Are pharmaceuticals cost-effective? A review of the evidence.
about
Bias in published cost effectiveness studies: systematic review.Pharmaceutical industry sponsorship and research outcome and quality: systematic reviewA systematic review of studies eliciting willingness-to-pay per quality-adjusted life year: does it justify CE threshold?Cost-effectiveness of extended release naltrexone to prevent relapse among criminal justice-involved individuals with a history of opioid use disorder.The value of specialty oncology drugs.Health Economics of Antibiotics.Routine echocardiography screening for asymptomatic left ventricular dysfunction in childhood cancer survivors: a model-based estimation of the clinical and economic effects.Cost-effectiveness of endoscopic surveillance of gastric ulcers to improve survivalDoes Medicare have an implicit cost-effectiveness threshold?Cost-effectiveness of treatment and endoscopic surveillance of precancerous lesions to prevent gastric cancer.What is the value for money of medicines? A registry study.Drug policy down under: Australia's pharmaceutical benefits scheme.What affects the quality of economic analysis for life-saving investments?Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination.The potential economic value of a 'universal' (multi-year) influenza vaccineA cost-utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer.The potential economic value of a Staphylococcus aureus vaccine among hemodialysis patients.Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis.An economic model assessing the value of microneedle patch delivery of the seasonal influenza vaccine.Effectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision AnalysisDo new cancer drugs offer good value for money? The perspectives of oncologists, health care policy makers, patients, and the general population.Cost-effectiveness analysis and HIV screening: the emergency medicine perspective.The economic value of screening haemodialysis patients for methicillin-resistant Staphylococcus aureus in the USA.The potential economic value of screening hospital admissions for Clostridium difficile.Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescentsCost-effectiveness analysis of whole-mount pathology processing for patients with early breast cancer undergoing breast conservationEconomic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphomaTesting women with endometrial cancer to detect Lynch syndrome.Is fidaxomicin worth the cost? An economic analysis.The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United StatesCost-effectiveness of multifaceted evidence implementation programs for the prevention of glucocorticoid-induced osteoporosis.Cost-effectiveness of targeted human immunodeficiency virus screening in an urban emergency department.Bevacizumab combination therapy: for the first-line treatment of advanced epithelial ovarian, fallopian tube or primary peritoneal cancer.Methodological reviews of economic evaluations in health care: what do they target?The economic burden of lung cancer and mesothelioma due to occupational and para-occupational asbestos exposure.A systematic review of health economic evaluations of vaccines in Brazil.Avoiding research waste through cost-effectiveness analysis: the example of medication adherence-enhancing interventions.Paying for personalized care: cancer biomarkers and comparative effectiveness.Examining the link between cash flow, market value, and research and development investment spending in the medical device industry.Valuing end-of-life care in the United States: the case of new cancer drugs.
P2860
Q24541365-A13763D3-56CA-4484-8E69-8238A1810710Q24673248-4583A527-B92B-47A5-913C-3078177CFA25Q27015133-2723B85C-F9D1-4CF3-9417-60F0C06CA3F8Q30253083-65F295CF-39FE-42C2-BFD4-7B43B0437C3AQ33618746-4EFF4E58-23B0-47FD-A157-4D48F63C961BQ33664262-A92D1BE9-7AB6-4377-B289-3D0E169671AEQ33873865-692A05EE-644A-4633-A2ED-B7237CFD1327Q33987025-E8D7ACAF-C4B8-4EC7-8120-626EB878EFA7Q34121002-09660753-5E63-4F4B-A24C-28EECC842E43Q34157164-4E249574-CF9C-43CC-AC12-44FDBD8B6BA6Q34205698-AF592874-D3F1-4A41-B9D9-207770083FDEQ34328049-8295A1C1-FF43-412B-B12F-5C2DEBBF027DQ34546567-2E5BA547-D331-4E4C-A041-5FD8E10E71DAQ34997604-2E3EF920-9A50-4A4F-8694-99D314F5CEA3Q35661358-C226FB0D-5A40-44A9-B7A5-3A32427CE244Q35883007-6BD7A3C2-DCF5-4C45-8882-9DFA1DADA9AAQ36020705-951BB2D4-E114-4349-ADB4-39A86E924981Q36069062-0AE6BBD3-665A-4943-B379-007A23F91D16Q36215695-374CED8D-3372-46A2-A238-B90F69D2021DQ36400944-FFFC4F9A-CBA5-435B-BEBF-A973A120471FQ36402852-9D317890-B619-4D36-89D2-AD75CD0C4DF3Q36435056-73F532FA-7A40-4798-905F-1658D32DCEC8Q36557836-E08AC211-2946-4631-8329-41CEEEC78498Q36582287-FF5917AE-2D14-4853-B5B2-A70B038E8901Q36623089-AFF16079-6DB4-4838-B3EC-E5ED179D6E20Q36658832-A1D7FC67-219D-4B53-B07D-39EB00B6C94EQ36726780-F6AD39E0-7219-43D8-B493-3478BF369E54Q36920374-4257BF21-8FAA-4F24-92C4-F6EA55607645Q37037009-76392E49-63AF-4E7B-A5EA-70D36DAEEEF3Q37268867-B1AC0B8A-17C3-402A-A03C-BBA539213A28Q37274269-53BD8614-02C4-4285-B7F2-5B6AF65068A9Q37901537-667BA673-325E-45CC-946C-C4A6F9723E7CQ38003707-CABAC680-AD8D-421D-99F7-85C0E40C4A34Q38131376-674C6FFC-FC74-4A1D-A40A-12CD37A84131Q38399562-74F265F1-70CF-4E88-AFC2-B47DC13FEF04Q38995392-4C76C5BC-A15E-410F-8881-11AA0B5A75A6Q39178628-185D717F-1783-422A-9A00-DC3BC3FCEC2EQ41376969-C02B3DFE-5498-4EAD-A784-575D7BE39853Q46320097-DE331B34-0574-4373-83EF-8D5061FA2F47Q47563275-8FD5D861-9691-4464-9A6B-066FA6F91B72
P2860
Are pharmaceuticals cost-effective? A review of the evidence.
description
2000 nî lūn-bûn
@nan
2000 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մարտին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Are pharmaceuticals cost-effective? A review of the evidence.
@ast
Are pharmaceuticals cost-effective? A review of the evidence.
@en
type
label
Are pharmaceuticals cost-effective? A review of the evidence.
@ast
Are pharmaceuticals cost-effective? A review of the evidence.
@en
prefLabel
Are pharmaceuticals cost-effective? A review of the evidence.
@ast
Are pharmaceuticals cost-effective? A review of the evidence.
@en
P2093
P356
P1433
P1476
Are pharmaceuticals cost-effective? A review of the evidence
@en
P2093
E A Sandberg
P J Neumann
R H Chapman
P304
P356
10.1377/HLTHAFF.19.2.92
P407
P50
P577
2000-03-01T00:00:00Z